Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006

MT Newswires Live

Jan 14

Ribomic (TYO:4591) has filed a new substance patent for RBM-006, a highly active anti-autotaxin (ATX) aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.

RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.

With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603986426"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603986426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603986426?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603986426","market":"sg","top_or_hot":-1,"title":"Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006","media":"MT Newswires Live","content":"<html><body><p> Ribomic (TYO:4591) has filed a new substance patent for RBM-006, a highly active anti-autotaxin (ATX) aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.</p><p>RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.</p><p>With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibomic Files Patent for Anti-Autotaxin Aptamer RBM-006\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-14 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ribomic (TYO:4591) has filed a new substance patent for RBM-006, a highly active anti-autotaxin (ATX) aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.</p><p>RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.</p><p>With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATX.AU","symbol_name":"AMPLIA THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603986426","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603986426","pubTimestamp":1768376683,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ribomic  has filed a new substance patent for RBM-006, a highly active anti-autotaxin  aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATX.AU":"AMPLIA THERAPEUTICS LTD","BK7067":"生物科技"},"translate_title":"Ribomic申请抗自分泌运动蛋白适体RBM-006专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATX.AU":1},"content_text":"Ribomic (TYO:4591) has filed a new substance patent for RBM-006, a highly active anti-autotaxin (ATX) aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}